Advanced Biomed (NASDAQ:ADVB) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Advanced Biomed (NASDAQ:ADVB) from a hold rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings cut shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Advanced Biomed presently has a consensus rating of “Sell”.

Advanced Biomed Trading Up 4.5%

Shares of ADVB stock opened at $4.16 on Friday. The firm has a market capitalization of $6.86 million, a price-to-earnings ratio of 0.86 and a beta of 0.01. The business’s 50-day moving average price is $7.47 and its 200-day moving average price is $6.46. Advanced Biomed has a 12 month low of $3.61 and a 12 month high of $24.23.

Advanced Biomed (NASDAQ:ADVB) last released its quarterly earnings data on Tuesday, October 13th. The company reported $0.44 earnings per share (EPS) for the quarter.

Advanced Biomed Company Profile

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.